Raising Capricor: Building a Biotech Company from Bench to Bedside
Linda Marban, CEO, Capricor Therapeutics
Linda Marban is currently CEO, President and Director of Caprico Therapeutics. She combines her background in research with her business experience to lead Capricor and create a path to commercialization for its novel stem-cell cardiac therapies. Dr. Marban was the lead negotiator in procuring the license agreements that are the foundation of Capricor’s intellectual property portfolio. Under her direction as Chief Executive Officer, Capricor secured approximately $27.0 million in nondilutive grants and a loan award which funds Capricor’s R&D programs and clinical trials involving its CAP-1002 product. Dr. Marban’s deep knowledge of the cardiac space in particular, allows her to provide unique direction for the company’s development and growth. From 2003 to 2009, Dr. Marban was with Excigen, Inc., a biotechnology start-up company, where she was responsible for business development, operations, pre-clinical research, and supervising the development of gene therapy products in a joint development agreement with Genzyme Corp. While at Excigen, she also negotiated a joint development and sublicense agreement with Medtronic Corp. utilizing Excigen’s technology and supervised the building of a lab in which the work was to be performed.
Dr . Marban began her career in academic science at the Cleveland Clinic Foundation working on the biophysical properties of cardiac muscle. She moved to a postdoctoral fellowship at Johns Hopkins University and advanced to the rank of Research Assistant Professor in the Department of Pediatrics, continuing her work on the mechanism of contractile dysfunction in heart failure. Dr. Marban earned a Ph.D. from Case Western Reserve University in cardiac physiology.